|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|109 - 9999|
Brexit and the Impact to Your Global Business Operations: What Life Sciences Companies Need to Know Now
Your international drug and device business is at a crossroads known as Brexit — the withdrawal of the United Kingdom (UK) from the European Union (EU).
What can you expect?
The EMA is moving to from London to Amsterdam in March 2019 — and will lose a 30 percent of its staff. The agency has already stopped accepting and publishing clinical trials data.
What about the legal uncertainty regarding contracts involving both the UK and other EU member states?
Brexit is about to happen and you need to make plans before it does. Prepare to discover:
Brexit will be finalized on March 29, 2019. You need to know how it will impact your global operations. Order today to minimize potential disruptions.
Any quality or regulatory professional at a life sciences company with operations involving the European Union and the United Kingdom including:
Michael Burke, Partner, Corporate Practice, Arnall Golden Gregory
Michael Burke provides practical and actionable legal and compliance guidance that allows companies to focus on business growth. He helps companies minimize risk and maximize return across a wide range of domestic and cross-border corporate and commercial transactions and regulatory issues. Mike is a partner in the Corporate Practice and co-chairs Arnall Golden Gregory’s Pharmaceuticals and Medical Devices Industry Team. Mike co-chairs the American Bar Association-United Nations Development Programme International Legal Resource Center and is the immediate past chair of the American Bar Association’s Section Officer’s Conference.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing